https://orcid.org/0000-0002-2043-4135
Figures
Abstract
Objectives
People with diabetes are at high risk of polypharmacy owing to complex treatment of diabetes and comorbidities. Polypharmacy is associated with increased risk of adverse reactions and decreased compliance. Therefore, the objectives of this study were to assess polypharmacy in people with type 2 diabetes (T2D) and associated diabetes-related factors in rural areas in Vietnam.
Method
People with T2D (n = 806) who had received treatment for diabetes at a district hospital were invited to participate in a questionnaire-based cross-sectional survey. Polypharmacy was defined as ≥5 types of medicine and assessed as a) prescription medicine and non-prescription/over the counter (OTC) medicine and b) prescription medicine and non-prescription/OTC, herbal and traditional medicine, and dietary supplement. Multiple logistic regression was used to investigate the association between polypharmacy and diabetes specific factors: duration, comorbidities and diabetes-related distress.
Results
Of the people with T2D, 7.8% had a medicine use corresponding to polypharmacy (prescription medicine and non-prescription/OTC), and 40.8% when herbal and traditional medicine, and dietary supplement were included. Mean number of medicine intake (all types of medicines and supplements) were 3.8±1.5. The odd ratios (ORs) of polypharmacy (medicine and supplements) increased with diabetes duration (<1–5 years OR = 1.66; 95%CI: 1.09–2.53 and >5 years OR = 1.74; 95%CI: 1.14–2.64 as compared to ≤1-year duration of diabetes), number of comorbidities (1–2 comorbidities: OR = 2.0; 95%CI: 1.18–3.42; ≥3 comorbidities: OR = 2.63;95%CI: 1.50–4.61 as compared to no comorbidities), and suffering from diabetes-related distress (OR = 1.49; 95%CI: 1.11–2.01) as compared to those without distress.
Conclusions
In rural northern Vietnam, persons with longer duration of T2D, higher number of comorbidities and diabetes-related stress have higher odds of having a medicine use corresponding to polypharmacy. A high proportion of people with T2D supplement their prescription, non-prescription/OTC medicine with herbal and traditional medicine and dietary supplements.
Citation: Thi Bui DH, Nguyen BX, Truong DC, Meyrowitsch DW, Søndergaard J, Gammeltoft T, et al. (2021) Polypharmacy among people living with type 2 diabetes mellitus in rural communes in Vietnam. PLoS ONE 16(4): e0249849. https://doi.org/10.1371/journal.pone.0249849
Editor: Vijayaprakash Suppiah, University of South Australia, AUSTRALIA
Received: September 15, 2020; Accepted: March 25, 2021; Published: April 8, 2021
Copyright: © 2021 Thi Bui et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting Information files.
Funding: Study was funded by the Ministry of Foreign Affairs of Denmark (DANIDA)
Competing interests: The authors have declared that no competing interests exist.
Introduction
The prevalence of diabetes among adults in Vietnam has increased from 2.7% in 2002 [1] to 6% in 2017 [2]. To prevent complications and comorbidities such as hypertension, heart disease and arthritis [2,3], people with diabetes must daily adhere to glucose-lowering medicine, monitor and test their blood glucose, address cardiovascular disease risk factors, including blood pressure [4] and lipid management [5,6], and often significantly change their diet and physical activity level [7]. Consequently, people living with diabetes often have to use multiple medicines for their diabetes, comorbidities and complications [8]. Concomitant use of multiple medicines can be harmful even when each drug is prescribed according to clinical guidelines because each additional medicine increases the risk of adverse reactions and decreased compliance [9].
The use of multiple medications is defined as “polypharmacy” [10]. There is no consensus on the definition of polypharmacy: polypharmacy has been defined both excluding [11] and including none-Western medications such as herbal and traditional medicine and dietary supplements [12]. Studies defining polypharmacy as only prescribed/OTC medicine have reported that polypharmacy is associated with adverse drug events, drug-drug interaction, hospitalization, cost [13], mortality, and morbidity [14]. Previous studies also showed that people with diabetes more often have medication use corresponding to polypharmacy than people without diabetes [11,15]. Further, polypharmacy reduces adherence to the medicine and decreases the quality of life in people with diabetes [14].
The majority of studies on polypharmacy in people with diabetes have been conducted in high-income countries, and very few have focused on middle-income countries such as Vietnam. A study from Vietnam showed that the rate of polypharmacy among hospitalized patients in general aged 60 years and older was 59.2% [16]. The proportion of people with diabetes with polypharmacy is not known. Therefore, a cross-sectional study was conducted to assess the proportion of adult Vietnamese age ≥40 year with type 2 diabetes (T2D) who have a medicine intake corresponding to polypharmacy and identify factors associated with polypharmacy.
Materials and methods
Study population and setting
A cross-sectional survey was conducted from December 2018 to February 2019 in Thai Binh Province, a province in North-eastern Vietnam. The total population is 1.86 million people, GDP per capita 1.650 USD, and more than 90% of the population live in rural areas [17]. Thai Binh Province is subdivided into seven districts and one provincial city and has a total of 9 townlets, 10 wards, and 267 communes.
The state health care system in Vietnam is organized as a four-tiered pyramid. At the top of the pyramid is the Ministry of Health, which subsumes provincial, district and commune health authorities. Thai Binh Province has 12 district hospitals and 2 private hospitals, which are equivalent to district hospitals. People with diabetes can receive treatment at any of these hospitals and they can change the hospital anytime they want.
Sampling method
Among the seven districts of Thai Binh Province, we selected two districts, Quynh Phu District in the north and Vu Thu District in the south. In each district, the two communes with the highest number of people with T2D were selected. Of these communes, we selected two neighboring commues as these were convenient for data collection. Thus, out of 68 towns/communes in two districts, 8 were selected.
People with T2D residing in the 8 selected communes who had received treatment for their diabetes at the 3 district hospitals in Quynh Phu District and Vu Thu District were invited to take part in the study. Information on name, address, and phone number for these people were based on hospital records and provided by the district hospitals. In Vietnam, hospitals diagnoses diabetes using the WHO criteria. From the 8 communes, 963 people with T2D were invited to participate in the study; 37 respondents refused to participate in the study (3.8%), while 78 respondents could not be found at the reported address or had relocated (8.1%). In Vietnam, age of onset of T2D has been shown to be in the fourth to fifth decade of life [18], while type 1 diabetes is generally diagnosed at younger ages [2]. Our target population was people with T2D, thus, to minimize the potential of misclassification we excluded those with diabetes diagnosed before 40 years of age and those who did not remember their age when diagnosed (n = 42, 4.4%). These criteria resulted in a cohort of 806 people with T2D (respondence rate: 83.7%).
Ethical approval
The study was approved by the Medical Ethics Committee of Thai Binh University of Medicine and Pharmacy, Vietnam, (decision 11/2018, 23rd November 2018). Written informed consent was obtained from each participant before data collection. Participants could withdraw at any time during the interview. The participants were interviewed in their homes or another place selected by them. The completed questionnaires were managed and stored securely at Thai Binh University of Medicine and Pharmacy, Vietnam.
Data collection
Data were collected using a structured and pilot-tested questionnaire. We trained 16 village health workers from 8 health stations in the 8 selected communes as interviewers at a 2-day workshop followed by field-based training and counseling to administer the questionnaires. The interviews were as arranged through the staff of the commune health station. To ensure the questions were culturally appropriate and could be understood by the study participants, the questionnaire was pilot tested first among village health workers and second among people admitted to the hospital for diabetes.
Study variables
Outcome.
The number of medicines was reported by the person with T2D during the interview, who was encouraged to report prescription medicines, OTC medicines they purchased, herbal and traditional medicine, and dietary supplements, and to show all the medicines they were taking daily.
Definition of polypharmacy. There is no general consensus for the definition of polypharmacy, but daily intake of ≥5 medicines is the most commonly used to defined polypharmacy [11,12,19]. However, the definition of what constitutes medicines varies by either excluding or including non-western medicines such as herbal and traditional medicine and dietary supplements [11,12]. In the present study, we created two variables for polypharmacy: a) one only including prescribed medicine and non-prescription/over the counter medicine (OTC); and b) a variable including prescribed medicine and non-prescription/OTC medicine, herbal and traditional medicine, and dietary supplements [12]. Polypharmacy was categorized as: no (0), yes (1). For modeling purposes, we used the second definition as herbal and traditional medicine, and dietary supplements are commonly used in Vietnam.
Exposure.
Our main exposures of interest were variables related to the participant’s T2D: duration of diabetes, physical health, number of comorbidities, and diabetes-related distress. All this information was self-reported. Comorbidities were coded as 0, 1–2 comorbidities, 3 or more comorbidities) [20]; and duration of diabetes as ≤1 year, >1–5 years, >5 years) [21]. Diabetes-related distress (no, yes) [22] was defined according to the Problem Areas in Diabetes 5 (PAID-5) scale [23].
Covariates.
Covariates were factors known to be associated with polypharmacy and were categorized as follows: Age (categorized as 40–54 years, 55–69 years, ≥70 years) [15], sex (man, woman) [11], education (primary school and below, middle school, college and above) [24]; economic status (poor/near-poor, medium, wealthy) [25]; occupation (unemployed, farmer, small trade/worker/government employee/private company, retired), marital status (married/living together, single/widowed/divorced) [26], and self-reported physical health (excellent/good, fair, poor/very poor) [27].
Statistical analysis
Data were double entered using Epidata version 3.1 (The Epidata Association), cleaned and exported to SPSS (IBM Statistical Package for Social Science software) version 22 for analysis. Statistics of continuous variables were described using mean and standard deviation (SD), and categorical variables were summarized by calculating the number and frequency distribution. Bivariate logistic regression analysis was used to calculate the odd ratios (ORs) for the association between polypharmacy and independent variables and only those independent variables satisfied p-value ≤0.1. Next, multiple logistic regressions were adjusted for all independent variable satisfied p-value ≤0.1 in the bivariate logistic regressions. Adjusted odds ratios (AOR) with a 95% confidence interval (95% CI) and p-values <0.05 were used to determine if a risk factor was statistically significantly associated with polypharmacy.
Results
Out of 806 people living with T2D, 425 (52.7%) were women. The majority of the respondents were in the age group 55–69 years (58.1%). Mean age of the participants was 65.2±9.0 years. Mean duration of diabetes was 5.9 years. One-third (33.3%) of respondents suffered from more than three comorbidities. Half of the respondents (50.0%) presented with diabetes-related distress.
Polypharmacy
Mean number of medicines was 3.8 (1.5) (including prescription/OTC medicine, herbal and traditional medicine, and dietary supplements), ranging from 0 to 9 medicines per individual (distribution of prescription/OTC medicines:1: 6.6%; 2: 15.1%; 3: 16.6%; 4: 52.7%; ≥5: 7.8%). Table 1 shows that 7.8% of participants had medicine intake corresponding to polypharmacy (using the definition including only prescribed medicine and OTC medicine), while 40.8% had polypharmacy according to the definition also including herbal and traditional medicine, and dietary supplements.
Table 2 shows the characteristics of people with T2D with and without polypharmacy (including herbal and traditional medicine and dietary supplements). Sex, marital status, occupation, education level, economic status and self-report of physical health did not differ between people with and without polypharmacy. Polypharmacy was associated with duration of diabetes, increasing number of comorbidities, and diabetes-related distress.
Factors associated with polypharmacy
The analysis of logistic regression indicated that the factors associated with polypharmacy were duration of diabetes above 1 year, presence of more than 1 comorbidity, and having diabaetes-related distress (Table 3). Compared to those without comorbidities, the ORs of polypharmacy in people with 1–2 comorbidities and ≥3 comorbidities were 2.01 and 2.63 respectively. Polypharmacy was associated with duration of diabetes: compared to those who had diabetes for ≤ 1 year, those with diabetes for 1–5 years and >5 years had higher ORs of polypharmacy was 1.66 and 1.74, respectively. People with diabetes-related distress had higher OR of polypharmacy as compared to those without diabetes-related distress (OR = 1.49).
Discussion
This study shows that among people with T2D in rural Vietnam, 7.8% has polypharmacy when defined as ≥5 prescribed/OTC medicines, and 40.8% when also including herbal, traditional medicine and dietary supplements in the polypharmacy definition. Polypharmacy was associated with longer duration of diabetes, increasing number of comorbidities and diabetes related to distress. There was no association between polypharmacy and demographic or socio-economic factors.
Studies from other countries have found the proportion of polypharmacy among people with diabetes range from 48% to 85% [11,15,21,28–30]. However, as definitions of polypharmacy vary, these data are not directly comparable. Thus, these studies defined polypharmacy as either prescription or OTC medicine [11], or only including prescribed medicine. When we defined polypharmacy including only prescribed medicines and OTC, only 7.8% had polypharmacy. This discrepancy may be partly explained by our study population: we included people with T2D who received treatment at a district hospital; in the Thai Binh, people with diabetes with more severe complications usually receive treatment at the provincial or national hospitals [31]. Moreover, most people with diabetes in Vietnam use health insurance to cover treatment and medicine for their disease and the insurance only covers the cost for a monthly check-up in district hospitals up to VND 223,500 (approximately 10 USD), including blood testing, medical examination fee, and medicine [32]. Thus, doctors may prescribe only the most important medicine/s to keep the cost within the limit.
When defining polypharmacy by including herbal and traditional medicine, the proportion of people with diabetes with polypharmacy was 40.8%, which suggests that people with substitute, supplement, or rely on non-pharmaceutical treatment for their diabetes. A study from Vietnam reported that reasons for this include people believing that a combination of conventional and herbal and traditional medicine will improve the effectiveness of their diabetes treatment [33]. A study conducted in the United States among Vietnamese immigrants showed that people with T2D even stop taking prescribed medicine when using traditional medicine because of worries of side effects of prescribed medicines [34]. Further, in Vietnam, using herbal and traditional medicine is considered a therapy with minimal or no side effect and entails lower financial costs [35,36]. This may be explained by traditional and herbal medicine having a long and honored history in Vietnam: for thousands of years, Vietnamese people have treated diseases with herbs and plants, which were gathered from gardens and forests. Thus, using traditional and herbal medicine is still an important component of national efforts to promote public health in urban and rural populations in Vietnam [37]. Nowadays, using traditional and herbal medicine are widely used beside Western medicine and traditional and herbal medicine are especially used when Western medicine is considered ineffective or too expensive [37].
In our study, longer duration of diabetes increased the ORs of polypharmacy. In studies conducted in China, Brazil and Italy among people with T2D showed that polypharmacy was associated with duration of T2D of ≥5 years [15,21,38]. Other studies have also showed an association between diabetes duration and diabetes- related complications and commorbidities [39,40]. Longer duration is associated with increasing risk of diabetes complications and comorbidities [41], which may require additional medicine [42]. The requirement of additional medicine may also explain our results showing that the ORs of polypharmacy were associated with higher number of comorbidities, which is in line with recently published studies [15,21,43–45]. People with T2D are at high risk of arterial hypertension, cardiovascular disorder, hyperlipidemia, ect.,—all conditions, which require medicine: antihypertensive, antihyperlipidemic, antiplatelets medicines are often co-prescribed along with antidiabetic medicine [46].
We found that the OR of polypharmacy was higher among those with diabetes-related distress than those without diabetes-related distress. The results of studies showing that polypharmacy is associated with psychological distress in general [11,22]. People with less well-controlled diabetes may have higher distress due to the difficulties managing their disease and therefore try out different medicines in an effort to better control their disease [36]. On the other hand, polypharmacy may increase the risk of hospitalizations, morbidity and financial cost [47], which may increase the emotional and financial stress for people with diabetes, especially those living in rural Vietnam areas where the average monthly income is around 100 US$ [36,48].
Limitations and strengths
To our knowledge, this study is the first to report about polypharmacy in people with T2D in Vietnam. We collected data in rural and semi-urban areas and had a response-rate of 84%.
This study also has some limitations; selection bias may have occurred since we only included patients who had received treatment for T2D at district hospitals, which may have excluded 1) people who control their diabetes with diet and physical activity only, and are not in contact with a district hospital; and 2) people who receive diabetes treatment at regional hospital or provincial hospitals, which typically treat more severe cases of diabetes. These people would likely have lower or higher OR of polypharmacy, respectively, and we might have overestimated or underestimated the proportion of people with T2D with polypharmacy. Furthermore, non-responders constituted around 13.5% of the sample, which may have influenced the results: we did not systematically collect data about them, but they mostly reported being unavailable for interview due to being at work, and may thus have been younger and in better health, and have had a lower medicine use than the people included in the study. This study examined the association of polypharmacy including prescription/OTC medicines, herbal, traditional medicine and dietary supplement, the results could be different if the study was limited to only people using prescription/OTC medicines. Our study was conducted in Vietnam and the results cannot be generalized to other populations. Lastly, we do not know the types of medicine which people with T2D were taking and we cannot assess if they were over or undertreated.
Conclusions
Less than 10% of the study population reported a medicine intake corresponding to polypharmacy defined as prescription and non-prescription/OTC medicine, while the proportion increased to 41% when including herbal and traditional medicine and dietary supplements. Polypharmacy was more common among those persons with longer duration of T2D, higher number of comorbidities and diabetes-related distress. The study findings suggest that a high proportion of people with T2D supplement their treatment with herbal and traditional medicine and dietary supplements. Further research should focus on whether people with T2D in Vietnam are undertreated or overtreated, and if those with polypharmacy experience harmful effects.
Supporting information
S1 Table. Frequency of other disease among peole with T2D.
https://doi.org/10.1371/journal.pone.0249849.s001
(PDF)
Acknowledgments
The present study is part of the interdisciplinary research project, Living Together with Chronic Disease: Informal Support for Diabetes Management in Vietnam (VALID) (17-M09-KU). This study is part of a collaborative project between ThaiBinh University of Medicine and Pharmacy and University of Copehagen of Denmar. We are grateful to the staff at three district hospitals and village health workers from 8 communes in Thai Binh province. We also thank all the people from Quynh Phu and Vu Thu district who participated in the interview
References
- 1. Nguyen CT, Pham NM, Lee AH, Binns CW. Prevalence of and Risk Factors for Type 2 Diabetes Mellitus in Vietnam: A Systematic Review. Asia Pac J Public Health. 2015;27(6):588–600. pmid:26187848
- 2.
International Diabetes Federation. Diabetes Atlas 7th edition. 2017.
- 3. Teljeur C, Smith SM, Paul G, Kelly A, O’Dowd T. Multimorbidity in a cohort of patients with type 2 diabetes. Eur J Gen Pract. 2013;19(1):17–22. pmid:23432037
- 4. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359(15):1565–76. pmid:18784091
- 5. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–25. pmid:18191683
- 6. Laakso M, Lehto S, Penttila I, Pyorala K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993;88(4 Pt 1):1421–30. pmid:8403288
- 7. Gonder-Frederick LA, Cox DJ, Ritterband LM. Diabetes and behavioral medicine: the second decade. J Consult Clin Psychol. 2002;70(3):611–25. pmid:12090372
- 8.
World Health Organization. Global report on diabetes. 2016.
- 9. Maher RL, Hanlon JT, Hajjar ER. Clinical Consequences of Polypharmacy in Elderly. Expert Opin Drug Saf. 2014;13(1). pmid:24073682
- 10. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. pmid:29017448
- 11. Alwhaibi M, Balkhi B, Alhawassi TM, Alkofide H, Alduhaim N, Alabdulali R, et al. Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. BMJ Open. 2018;8(5):e020852. pmid:29794097
- 12.
World Health Organization. Medication safety in Polypharmacy; 2019.
- 13. Byles JE, Heinze R, Nair BK, Parkinson L. Medication use among older Australian veterans and war widows. Intern Med J. 2003;33(8):388–92. pmid:12895173
- 14. Thommanduru Priyanka AL, Alluru Revanth, Chakka Gopinath and Singanamalla Chandra Babu. Effect of Polypharmacy on Medication Adherence in Patients with Type 2 Diabetes mellitu. Indian Journal of Pharmacy Practice. 2015;8(3).
- 15. Silva M, Diniz LM, Santos J, Reis EA, Mata ARD, Araujo VE, et al. Drug utilization and factors associated with polypharmacy in individuals with diabetes mellitus in Minas Gerais, Brazil. Cien Saude Colet. 2018;23(8):2565–74. pmid:30137126
- 16. Nguyen TX, Nguyen TN, Nguyen AT, Nguyen HTT, Nguyen TTH, Nguyen TN, et al. Polypharmacy at discharge in older hospitalised patients in Vietnam and its association with frailty. Australas J Ageing. 2019. pmid:31677221
- 17.
Investment promotion center for North Vietnam [Internet]. 2018. Available from: http://ipcn.vn/en/regions/detail/135/thai-binh.html.
- 18. Khue NT. Diabetes in Vietnam. Ann Glob Health. 2015;81(6):870–3. pmid:27108154
- 19. Haider SI, Johnell K, Thorslund M, Fastbom J. Analysis of the association between polypharmacy and socioeconomic position among elderly aged > or = 77 years in Sweden. Clin Ther. 2008;30(2):419–27. pmid:18343279
- 20. Geitona M, Latsou D, Toska A, Saridi M. Polypharmacy and Adherence Among Diabetic Patients in Greece. Consult Pharm. 2018;33(10):562–71. pmid:30322433
- 21. Li J, Chattopadhyay K, Xu M, Chen Y, Hu F, Wang X, et al. Prevalence and predictors of polypharmacy prescription among type 2 diabetes patients at a tertiary care department in Ningbo, China: A retrospective database study. PLoS One. 2019;14(7):e0220047. pmid:31314797
- 22. Assari S, Bazargan M. Polypharmacy and Psychological Distress May Be Associated in African American Adults. Pharmacy (Basel, Switzerland). 2019;7(1):14. pmid:30682807
- 23. McGuire BE, Morrison TG, Hermanns N, Skovlund S, Eldrup E, Gagliardino J, et al. Short-form measures of diabetes-related emotional distress: the Problem Areas in Diabetes Scale (PAID)-5 and PAID-1. Diabetologia. 2010;53(1):66–9. pmid:19841892
- 24. Haider SI, Johnell K, Weitoft GR, Thorslund M, Fastbom J. The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600,000 older people. J Am Geriatr Soc. 2009;57(1):62–9. pmid:19054196
- 25. Josephine Valsa Jose PD, Satish Renuka. Polypharmacy and predictors of high level polypharmacy in patients with diabetic nephropathy in a tertiary care hospital. Medicine. 2019.
- 26. Wawruch M, Zikavska M, Wsolova L, Kuzelova M, Tisonova J, Gajdosik J, et al. Polypharmacy in elderly hospitalised patients in Slovakia. Pharmacy World & Science. 2008;30(3):235–42. pmid:17943457
- 27. Bazargan M, Smith J, Saqib M, Helmi H, Assari S. Associations between Polypharmacy, Self-Rated Health, and Depression in African American Older Adults; Mediators and Moderators. International journal of environmental research and public health. 2019;16(9):1574.
- 28.
Rutters F, Oort Sv, Kramers K, Elders P. The characterisation of people with type 2 diabetes and polypharmacy in the Netherlands: the Diabetes Pearl cohor. Berlin The European Association for the Study of Diabetes; 2018.
- 29. Gadsby R, Galloway M, Barker P, Sinclair A. Prescribed medicines for elderly frail people with diabetes resident in nursing homes-issues of polypharmacy and medication costs. Diabet Med. 2012;29(1):136–9. pmid:22004423
- 30. da Silva Corralo V, Marconatto Binotto V, Bohnen LC, Gonzaga Dos Santos GA, De-Sa CA. Polypharmacy and associated factors in elderly diabetic. Rev Salud Publica (Bogota). 2018;20(3):366–72. pmid:30844011
- 31. Nguyen T, Knight R, Mant A, Cao Q, Auton M. Medicine prices, availability, and affordability in Vietnam. Southern Med Review. 2009;2:2–9. pmid:23093870
- 32.
Security VS. Direct payment of expenses of medical examination and treatment covered by medical insurance. 2019.
- 33. Kasole R, Martin HD, Kimiywe J. Traditional Medicine and Its Role in the Management of Diabetes Mellitus: "Patients’ and Herbalists’ Perspectives". Evid Based Complement Alternat Med. 2019;2019:2835691. pmid:31354852
- 34. Mull DS, Nguyen N, Mull JD. Vietnamese diabetic patients and their physicians: what ethnography can teach us. The Western journal of medicine. 2001;175(5):307–11. pmid:11694472
- 35. Ung L, Lay H-L, Wu M-C. Herbs for the Management of Diabetes Mellitus in Traditional Vietnamese Medicine. Journal of Applied Biopharmaceutics and Pharmacokinetics. 2019;7:1–7.
- 36. Dieu BTH. Non-using diabetic medication in health insurance–some reasons need special attention Vietnam Medical Journal. 2019;483(1).
- 37. Loi DT, Duñg NX. Native drugs of Vietnam: which traditional and scientific approaches? J Ethnopharmacol. 1991;32(1–3):51–6. pmid:1881167
- 38. Noale M, Veronese N, Cavallo Perin P, Pilotto A, Tiengo A, Crepaldi G, et al. Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment. Acta Diabetol. 2016;53(2):323–30. pmid:26155958
- 39. Karlsen B, Oftedal B, Bru E. The relationship between clinical indicators, coping styles, perceived support and diabetes-related distress among adults with type 2 diabetes. J Adv Nurs. 2012;68(2):391–401. pmid:21707728
- 40. Kasteleyn MJ, de Vries L, van Puffelen AL, Schellevis FG, Rijken M, Vos RC, et al. Diabetes-related distress over the course of illness: results from the Diacourse study. Diabetic Medicine. 2015;32(12):1617–24. pmid:25763843
- 41. Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ. Prevalence of Diabetic Complications in Relation to Risk Factors. Diabetes. 1986;35(12):1332–9. pmid:3770311
- 42. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93. pmid:12556541
- 43. Horii T, Iwasawa M, Kabeya Y, Atuda K. Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis. Sci Rep. 2019;9(1):12992. pmid:31506542
- 44. Austin RP. Polypharmacy as a Risk Factor in the Treatment of Type 2 Diabetes. Diabetes Spectrum. 2006;19(1):13–6.
- 45. Dobrica EC, Gaman MA, Cozma MA, Bratu OG, Pantea Stoian A, Diaconu CC. Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department. Medicina (Kaunas). 2019;55(8). pmid:31382651
- 46. Indu R, Adhikari A, Maisnam I, Basak P, Sur T, Das A. Polypharmacy and comorbidity status in the treatment of type 2 diabetic patients attending a tertiary care hospital: An observational and questionnaire-based study. Perspectives in Clinical Research. 2018;9(3):139–44. pmid:30090713
- 47. Wimmer BC, Bell JS, Fastbom J, Wiese MD, Johnell K. Medication Regimen Complexity and Number of Medications as Factors Associated With Unplanned Hospitalizations in Older People: A Population-based Cohort Study. The Journals of Gerontology: Series A. 2015;71(6):831–7. pmid:26707381
- 48.
Vietnam Monthly Income per capita: Rural [Internet]. 2017. Available from: https://www.ceicdata.com/en/vietnam/monthly-income-per-capita/monthly-income-per-capita-rural.